Please assess the completion status of the following clinical trial:

Trial Title: LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Histologically confirmed American Joint Committee on Cancer seventh edition clinical stage T2-4a N0-3 urothelial carcinoma of the bladder based on diagnostic transurethral bladder biopsy or transurethral resection of bladder tumor (TURBT) confirming the presence of urothelial carcinoma with muscularis propria invasion.~* Archived tissue from prior biopsy/resection must be available for baseline AK analysis.~* Subjects must be eligible to undergo radical cystectomy and cisplatin-based chemotherapy.~* Subjects with radiographically enlarged lymph nodes (short axis \>10 mm with CT scan or MRI) should undergo percutaneous biopsy for staging in accordance with local practices, though preferred, is not mandatory for study enrollment.~* A baseline computed tomography (CT) scan with intravenous contrast of the chest, abdomen and pelvis is required in all subjects. A radionuclide bone scan is also required in subjects with skeletal pain or abnormally elevated alkaline phosphatase values.~* Age at least 18 years old.~* ECOG performance status of 0 or 1.~* Bilirubin less than 1.5 mg/dL.~* Subjects must have adequate liver function: AST and ALT less than 2.5x upper limit of normal, alkaline phosphatase less than 2.5x upper limit of normal.~* Subjects must have adequate bone marrow function: Platelets greater than 100,000 cells/mm3, Hemoglobin greater than 9.0g/dL and ANC greater than 1,500 cells/mm3.~* Subjects must have adequate renal function with creatinine clearance of at least 60 mL/min.~* Subjects must sign a written informed consent document and authorization for release of their medical records for the purposes of research.~Exclusion Criteria~* Pure non-urothelial or mixed small cell histology identified within TURBT specimen.~* Absence of documented urothelial carcinoma with muscularis propria invasion on diagnostic transurethral bladder biopsy or transurethral resection of bladder tumor (TURBT).~* Distant metastatic disease, including non-regional lymphadenopathy and visceral metastases, identified on pretreatment radiographic studies.~* Creatinine clearance less than 60 mL/min.~* CTCAE version 4 grade 2 or greater hearing loss.~* CTCAE version 4 grade 2 or greater peripheral neuropathy.~* NYHA class III heart failure or cardiac ejection fraction less than or equal to 50%.~* Women of child-bearing age who are pregnant or breast feeding.~* Uncontrolled and current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Subjects with other active malignancies as defined as synchronous malignancy at the time of bladder cancer diagnosis, excluding non-metastatic, non-melanoma skin cancer are excluded.~* Major surgery within 4 weeks of consent.~* Subjects requiring therapeutic anticoagulation at the time of consent.~* Currently enrolled on another clinical trial for the treatment of bladder cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: None): Specimen Collection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy